Anteris Technologies treats 100+ patients with DurAVR THV for aortic stenosis

Multinational company Anteris Technologies Global Corp, is a head in Structural heart solutions, and it has reached an essential achievement with its DurAVR Transcatheter Heart valve(THV). Over 100 patients suffering from severe aortic stenosis are now being treated. This development is highlighted by Anteris's dedication to enhancing cardiac care and could potentially impact the market for aortic valve replacements. 

Promising results with DurAVR THV have been shown by Anteris Technologies, Listed on NASDAQ and ASX under the ticker AVR. The Valve is layouts to imitate the natural aortic valve function, which has been to bring action across various complex cases, which includes those with distinctive anatomical challenegs like bicuspid aortic valves. Positive 30 day efficiency results have been reported by the company in 65 patients, alongside impressive one-year outcomes 37, indicating robust long- term performance and an excellent safety profile without cardiovascular-related mortalities, and it is an important milestone. 

 The financial stability of Anteris, characterized by a healthy current ratio and substantial cash reserves, is positioned well for continued innovation and the upcoming pivotal trial, which is slated for late 2025 pending FDA approval. The achievement of Anteris Technologies with the DurAVR THV is not only highlighted by its dedication to heart care invention but also favorable progression in the crucial market ,and  structural heart devices is set.